Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Inovio Pharmaceuticals
With
University of Pennsylvania
University of North Carolina
Thomas Jefferson University
University of Pittsburgh
Barbara Ann Karmanos Cancer Institute
Mayo Clinic
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Signed and dated written IRB approved informed consent;
2\. Males or females aged ≥18 years;
3\. Subjects with breast, lung or pancreatic carcinoma who are at high risk of relapse post definitive therapy at least 4 and no more than 24 weeks from completion of definitive therapy at the time of signing informed consent as described below for each indication:
* Breast carcinoma:
* Lung carcinoma:
* Pancreatic carcinoma:
* Head and neck squamous cell carcinoma:
* Ovarian cancer:
* Colorectal cancer
* Gastric and esophageal cancer
* Hepatocellular carcinoma
You may not be if
1\. Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA immunotherapy;
2\. Any concurrent condition requiring the continued or anticipated use of systemic steroids (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low dose methotrexate). All other systemic corticosteroids must be discontinued at least 4 weeks prior to first Study Treatment;
3\. Administration of any vaccine within 4 weeks of the first study treatment
Clareo Health | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
